Head to Head Contrast: Zenas BioPharma (NASDAQ:ZBIO) & BioCryst Pharmaceuticals (NASDAQ:BCRX)

Zenas BioPharma (NASDAQ:ZBIO) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, valuation, analyst recommendations and dividends.

Institutional & Insider Ownership

85.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. 22.0% of Zenas BioPharma shares are owned by company insiders. Comparatively, 3.8% of BioCryst Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and recommmendations for Zenas BioPharma and BioCryst Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zenas BioPharma	1	2	6	0	2.56
BioCryst Pharmaceuticals	1	2	6	0	2.56

Zenas BioPharma presently has a consensus target price of $46.71, suggesting a potential upside of 64.24%. BioCryst Pharmaceuticals has a consensus target price of $20.38, suggesting a potential upside of 167.92%. Given BioCryst Pharmaceuticals’ higher probable upside, analysts plainly believe BioCryst Pharmaceuticals is more favorable than Zenas BioPharma.

Valuation & Earnings

This table compares Zenas BioPharma and BioCryst Pharmaceuticals”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zenas BioPharma	$10.00 million	185.38	-$377.74 million	($9.42)	-3.02
BioCryst Pharmaceuticals	$874.84 million	2.24	$263.86 million	($1.42)	-5.36

BioCryst Pharmaceuticals has higher revenue and earnings than Zenas BioPharma. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Zenas BioPharma, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Zenas BioPharma and BioCryst Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Zenas BioPharma	N/A	-136.40%	-61.40%
BioCryst Pharmaceuticals	-37.40%	-92.91%	66.56%

Volatility & Risk

Zenas BioPharma has a beta of -0.88, meaning that its stock price is 188% less volatile than the S&P 500. Comparatively, BioCryst Pharmaceuticals has a beta of 0.55, meaning that its stock price is 45% less volatile than the S&P 500.

Summary

BioCryst Pharmaceuticals beats Zenas BioPharma on 8 of the 12 factors compared between the two stocks.

About Zenas BioPharma

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.